Easton Pharmaceuticals Signs "Viorra" Distribution Deal for Mexico
April 14 2014 - 8:00AM
Marketwired
Easton Pharmaceuticals Signs "Viorra" Distribution Deal for Mexico
TORONTO, ON--(Marketwired - Apr 14, 2014) - Easton
Pharmaceuticals (OTC: EAPH) is pleased to announce that BMV Medica,
S.A. de C.V., a Mexican regulatory company and distributor of
pharmaceutical products have signed an exclusive agreement to
distribute Easton's "VIORRA" product in Mexico.
Carla Pepe, CEO of Easton Pharmaceuticals, stated, "BMV Medica,
as previously announced, is the company's current regulatory
consultant for Mexico and other parts of Latin America. After
extensive discussions Easton has finalized a deal whereby BMV
Medica will take over Marketing and Distribution for VIORRA." Mrs.
Pepe further commented, "They have shown a strong interest in the
growth of VIORRA in Mexico, and expect to launch VIORRA later this
year, subject to the regulatory approvals and finalizing the
sourcing out of a suitable manufacturing partner. Discussions with
possible manufacturers are well under way and BMV anticipates
finalizing a deal shortly."
Ms. Mendoza Vazquez, of BMV Medica, stated, "BMV has launched
several products in Mexico recently, including pregnancy tests, and
several antibiotics. BMV is pleased to have obtained the
distribution rights to market and sell VIORRA in Mexico. Our market
analysis reveals, of the overall 120 million population within
Mexico, the potential VIORRA demographic could reach into the tens
of millions of women." Ms. Vazquez further commented, "We have
structured what we believe is a well-thought out marketing plan
which includes spokespersons, retail channels, and online sales to
ensure coverage across all sectors of the market. VIORRA will be
marketed as a premium, feminine daily-use product, and we expect it
to perform very well."
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
involved in various industries including medical marijuana that
also owns, designs, develops, and markets topically-delivered drugs
and therapeutic / cosmetic healthcare products, focused on cancer
and other health issues related towards male and female sexual
dysfunction, wound healing, pain, motion sickness, scar and stretch
marks, cellulite, varicose veins and other conditions. The company
is also endeavoring to enter other potentially lucrative industries
such as medical marijuana. The company's gel formulation is thought
to be an innovative and unique transdermal delivery system. Easton
Pharmaceuticals' product "VIORRA" is an over-the-counter
aid for the treatment to restore and improve vaginal moisture and
elasticity which is believed to have a positive effect on women's
sexual desire and arousal, FSAD (Female Sexual Arousal Disorder);
the world market for these female conditions is conservatively
estimated to be in the billions. VIORRA is a topical,
daily-use product classified by the FDA as containing Generally
Recognized as Safe ingredients.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
Safe Harbor This news release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (The "Act"). In particular, when used in the
preceding of discussion, the words "anticipate," "pleased," "plan,"
"confident that," "believe," "expect," "possible" or "intent to"
and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the
forward-looking statements. There are no guarantees or assurances
that any proposals, initiatives or negotiations will result in what
the company had originally intended. Any investment made into
Easton Pharmaceuticals would be classified as speculative and
risky. Such risks and uncertainties include, but are not limited
to, market conditions, general acceptance of the company's products
and technologies, competitive factors, the ability to successfully
complete additional or adequate financing, government approvals or
changes to proposed laws and other risks and uncertainties further
stated in the company's financial reports and filings.
Contact: Carla Pepe Kent Deuters Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291 Tel: +1(347) 284-0192 Email:
info@eastonpharmaceuticalsinc.com Email:
legal@eastonpharmaceuticalsinc.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Aug 2023 to Aug 2024